drugset / Trial / NCT02226952
Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
Study to assess the antiviral efficacy, pharmacokinetics and tolerability of BILN 2061 ZW in a polyethyleneglycol 400 (PEG 400: ethanol) drinking solution given for two days bid in patients with chronic Hepatitis C Virus (HCV) infection.
Timeline
- Start
- 2001-11
- Primary completion
- 2002-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BILN 2061 W | Unknown | 25 mg | Oral |
| Subject | BILN 2061 W | Unknown | 200 mg | Oral |
| Subject | BILN 2061 W | Unknown | 500 mg | Oral |